Current Surgical Receives $400k Grant from NIH's National Cancer Institute to Develop Surgery Platform for Early-Stage Cancer

Current Surgical Inc., a medical technology company, has been awarded a $400,000 grant by the National Institutes of Health's National Cancer Institute (NCI) to support the advancement of their surgical platform for early-stage cancer. The grant will be utilized to further develop and validate the company's innovative technology in a preclinical setting. With over 18 million new cases detected a..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 13.
  • textsms

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. has recruited the first patient in its revised SHIELD II Phase 3 trial for D-PLEX100, a late-stage biopharma product aimed at preventing abdominal colorectal surgical site infections. The US Food and Drug Administration recently accepted the company’s revised protocol for the study, which will enroll an estimated 550 patients undergoing colorectal resection surgery with large incisi..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 23.
  • textsms